Daratumumab for Late Antibody-Mediated Rejection
Recruiting
N/A
Interventional Study
Kidney Tansplant
Acute Rejection (AR) of Transplanted Kidney
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 20 (estimated)
- Sponsor
- University Hospital, Martin · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study titled "Daratumumab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo Donor-Specific Antibodies" (DARTABMR) is a case-control investigation assessing whether daratumumab is more effective than standard therapies (such as IVIG, plasmapheresis, and rituximab) in treating late antibody-mediated rejection (ABMR) in kidney transplant patients with new donor-spe…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Kidney transplant recipient (first or subsequent transplant)
* Diagnosis of late ABMR (diagnosed \>12 months post-transplant)
* Biopsy-proven ABMR
* Presence of de novo DSA
Exclusion Criteria:
* Active infection
* Other significant comorbidities that could affect outcomes or…
Contacts